Cadrenal Therapeutics, Inc. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 22/100
What the filing says
Cadrenal Therapeutics issued pre-funded warrants (exercise price $0.0001/share), Series C-1 warrants ($3.00/share, 5-year term), Series C-2 warrants ($3.00/share, 24-month term), and placement agent warrants ($3.91/share, 5-year term) dated June 30, 2026, under a Securities Purchase Agreement. Specific share counts and total proceeds are not disclosed in the exhibits; the filing contains only form templates with blank spaces for amounts. The document provides comprehensive warrant mechanics including cashless exercise rights, anti-dilution adjustments, and fundamental transaction protections.
Why this rating
Warrant issuance is routine capital structure event. Share counts and proceeds blank; relative magnitude to $24.9M company unknown. Forms only; no executed terms disclosed.
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.